3,4-dihydroxyphenylacetic acid has been researched along with ly 2140023 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ackermann, B; Anderson, S; Ayan-Oshodi, M; Dean, R; Eckstein, J; Ho, M; Jackson, K; Lowe, S; McKinzie, D; Natanegara, F; Perry, K; Svensson, K; Yuen, E | 1 |
1 trial(s) available for 3,4-dihydroxyphenylacetic acid and ly 2140023
| Article | Year |
|---|---|
Effects of a novel mGlu₂/₃ receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adult; Amino Acids; Animals; Biomarkers, Pharmacological; Bridged Bicyclo Compounds, Heterocyclic; Cyclic S-Oxides; Dopamine; Dose-Response Relationship, Drug; Homovanillic Acid; Humans; Injections, Intraperitoneal; Male; Microdialysis; Prodrugs; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Serotonin; Single-Blind Method; Young Adult | 2012 |